Clinical trials: Partial Seizures
Idiopathic Generalized Epilepsy, Partial Onset Seizures
A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial…
- Conditions
- Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures
- Trial name
- NCT04252846
- Testing
- Perampanel
- Where
- 36 sites in Denmark, France and 5 more
- Volunteers
- 191 people
- Sponsor
- Eisai Limited
Seizures, Epilepsy
Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery
This study will asses the safety and efficacy of BGG492 in reducing the seizure rate in therapy-refractory partial seizures.
- Trial name
- NCT00887861
- Testing
- Investigational new drug, company code: BGG492
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Novartis
Partial-onset Seizures With or Without Secondary Generalisation
Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult
A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine…
- Trial name
- NCT04095182
- Testing
- Zebinix 400mg, Zebinix 800mg, Zebinix 1600mg
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Whanin Pharmaceutical Company
Epilepsy With Partial On-set Seizures
A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures
A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures
- Trial name
- NCT03116828
- Testing
- Eslicarbazepine acetate
- Where
- 55 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Sumitomo Pharma America, Inc.
Epilepsy
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel…
- Trial name
- VERVE (NCT01484977)
- Testing
- Lacosamide
- Where
- 54 sites in United States, Australia and 7 more
- Volunteers
- 120 people
- Sponsor
- UCB Pharma
Focal Epilepsy
The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study
Unlike the first generation antiepileptic medications, newer drugs for epilepsy such as levetiracetam are reported to have less adverse effect in children but not many studies have systematically reviewed the subject.
- Trial name
- NCT02208492
- Testing
- Levetiracetam, Carabamazepine
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Yonsei University
Epilepsy
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the…
- Trial name
- NCT00310375
- Testing
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Where
- 51 sites in United States, Argentina and 3 more
- Volunteers
- 181 people
- Sponsor
- GlaxoSmithKline
Epilepsy, Partial
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
- Trial name
- NCT00160654
- Testing
- Levetiracetam
- Where
- 29 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 251 people
- Sponsor
- UCB Pharma
Focal Epilepsy
ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures
The ENACT trial is designed to evaluate the efficacy and safety of ENX-101 administered adjunctively to current therapy in reducing seizure frequency in patients diagnosed with focal (partial onset) epilepsy and treated with 1 to…
- Trial name
- ENACT (NCT05481905)
- Testing
- ENX-101
- Where
- 38 sites in United States
- Sponsor
- Engrail Therapeutics INC
Seizures
A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures
The purpose of this study is to evaluate the pharmacokinetics safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures.
- Trial name
- NCT00233012
- Testing
- Topiramate
- Volunteers
- 16 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy With Uncontrolled Focal-onset Seizures
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures.
- Trial name
- NCT06922175
- Where
- 10 sites in Germany, Netherlands and 3 more
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Drug Resistant Partial Onset Seizure
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
A follow-on, two-year open-label extension study of ganaxolone as add-on therapy in adult patients with drug-resistant partial-onset seizures
- Trial name
- NCT02519439
- Testing
- ganaxolone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Marinus Pharmaceuticals
Seizures
Pregabalin In Partial Seizures Extension Study
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
- Trial name
- PREPS EXT (NCT00143130)
- Testing
- Pregabalin
- Where
- 47 sites in Belgium, Finland and 4 more
- Volunteers
- 227 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Refractory Epilepsy
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization
This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal…
- Trial name
- NCT04153175
- Testing
- ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
- Where
- 11 sites in Australia, Israel
- Volunteers
- 30 people
- Sponsor
- Cerebral Therapeutics LLC
Focal Seizure
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)
- Trial name
- POWER1 (NCT06999902)
- Testing
- 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
- Where
- 69 sites in United States, Brazil and 5 more
- Volunteers
- 255 people
- Sponsor
- Praxis Precision Medicines
Epilepsy, Partial-Onset Seizures
Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.
- Conditions
- Epilepsy, Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT02736162
- Testing
- No treatment (intervention) was administered
- Volunteers
- 61 people
- Sponsor
- Eisai Inc.
Partial Seizures
Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID (75 to 300mg day titration…
- Trial name
- PREPS MEXICO (NCT00407797)
- Testing
- Pregabalin
- Where
- 8 sites in Mexico
- Volunteers
- 136 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
The purpose of this study is to systematically and prospectively collect data from patients with partial-onset seizures in routine clinical practice setting receiving adjunctive Vimpat®.
- Trial name
- VITOBA (NCT01098162)
- Where
- 113 sites in Germany
- Volunteers
- 576 people
- Sponsor
- UCB Pharma GmbH
Partial Seizures
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.
- Trial name
- PEACH (NCT03340064)
- Testing
- Levetiracetam
- Where
- 21 sites in Japan
- Volunteers
- 38 people
- Sponsor
- UCB Japan Co. Ltd.
Focal Epilepsy, Generalized Seizure
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Trial name
- FORESITE (NCT07012148)
- Testing
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic